Takeda Pharmaceutical Company Limited TKPHF
OTC PK
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -1.11% | -0.07% | 0.91% | 3.07% | -4.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.11% | -0.07% | 0.91% | 3.07% | -4.63% |
| Cost of Revenue | -4.37% | -4.16% | 17.94% | -4.78% | -2.85% |
| Gross Profit | 0.57% | 2.11% | -8.44% | 7.57% | -5.53% |
| SG&A Expenses | -0.66% | 1.51% | -4.15% | 3.42% | -4.75% |
| Depreciation & Amortization | -36.72% | -26.03% | -26.02% | 0.42% | -12.67% |
| Other Operating Expenses | -145.77% | 101.41% | 26.71% | -52.60% | 199.13% |
| Total Operating Expenses | -13.42% | -1.46% | 0.90% | -7.12% | 3.63% |
| Operating Income | 75.65% | 7.64% | 0.97% | 952.52% | -36.29% |
| Income Before Tax | 413.18% | -2.07% | -311.84% | 401.64% | -76.21% |
| Income Tax Expenses | -184.77% | 70.16% | -1,902.31% | 1,059.27% | 47.50% |
| Earnings from Continuing Operations | 1,620.91% | -17.39% | -247.03% | 330.67% | -112.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 62.66% | -51.06% | -5.64% | -102.22% | -18.96% |
| Net Income | 1,611.41% | -17.40% | -246.90% | 331.11% | -112.92% |
| EBIT | 75.65% | 7.64% | 0.97% | 952.52% | -36.29% |
| EBITDA | 24.73% | -5.97% | -13.19% | 58.99% | -21.65% |
| EPS Basic | 1,595.86% | -18.21% | -247.22% | 332.93% | -112.96% |
| Normalized Basic EPS | 96.64% | 7.63% | -38.78% | 342.27% | -41.97% |
| EPS Diluted | 1,572.19% | -18.24% | -247.22% | 325.71% | -113.18% |
| Normalized Diluted EPS | 93.54% | 7.56% | -38.78% | 338.30% | -40.99% |
| Average Basic Shares Outstanding | 1.10% | 0.97% | -0.10% | -0.39% | -0.34% |
| Average Diluted Shares Outstanding | 2.73% | 1.04% | -0.10% | 1.28% | -1.99% |
| Dividend Per Share | -5.46% | -- | -0.90% | -- | 2.85% |
| Payout Ratio | 1.05% | 0.13% | 0.75% | -0.76% | -8.45% |